President Donald Trump has earned capital gains from Regeneron Pharmaceuticals and Gilead Sciences Inc., the two biotechnology companies that have created drugs that are aiding Trump in his COVID-19 treatment. Since being diagnosed last week, Trump has been given an eight-gram dose of Regeneron’s antiviral cocktail and is on a five-day treatment of Gilead Science’s Remdesivir.
According to a 2017 financial disclosure form that was filed with the U.S. Office of Government Ethics, Trump had a capital gain of $50,001 to $100,000 for Regeneron Pharmaceuticals and $100,001 to $1 million for Gilead Sciences Inc.
Regeneron’s chief executive and a member of Trump’s golf club in Westchester County, New York, Dr. Leonard S. Schleifer, said Trump’s medical staff reached out to the company for permission to use the Regeneron’s REGN-COV2 cocktail drug, and the Food and Drug Administration cleared it.
It was unclear Saturday whether Trump currently has any direct stakes in Regeneron and Gilead.
